Sagard Healthcare Royalty Partners invests in the top-line revenues of businesses in the biopharmaceutical industry globally.
We focus on investments in approved and commercialized biopharmaceuticals, diagnostics, and medical devices that are protected by strong intellectual property.
Sagard’s healthcare royalties business is led by a team that has worked together at global institutions – David MacNaughtan, Ali Alagheband and Raja Manchanda.
Investment approach and value proposition
- We are a proven team of industry experts with deep experience in a complex investment strategy and a history of working together
- We have a flexible mandate including royalties and royalty-backed credit to match the right type of investment to each opportunity, and direct capital to areas of higher relative value
- Our focus on the long-term enables value maximization for both sides in a transaction
- As part of the Sagard platform, we have access to a strong operational infrastructure, business support, and network, enabling our team to focus on investments that accelerate the returns on innovation in the healthcare industry
We acquire royalties, provide royalty-backed loans, and invest directly in approved biopharmaceuticals, diagnostics, and medical devices in return for a royalty on direct sales
Investment size between US$25M to US$150M